Ownership and insider activity for Perspective Therapeutics, Inc. (CATX): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Perspective Therapeutics, Inc., including its various operations, specializes in the comprehensive lifecycle – from development and manufacturing to sales and marketing – of radiopharmaceutical products and medical devices. These advanced solutions are designed to treat cancer and other serious malignant conditions, serving markets both within the United States and globally. A flagship product offered by the company is its CS-1 Cesium-131 brachytherapy seeds.
Price
| Price | $2.88 |
| Market Cap | $328M |
| Exchange | AMEX |
| Country | US |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.9M | $2.6M | $5.3M | $2.4M | $9.6M | $55.9M | $21.0M | $9.2M | $61.6M | $30.6M |
| Short-term Investments | $3.0M | $825000 | 0 | 0 | 0 | 0 | $22.8M | 0 | $165.3M | $114.1M |
| Receivables | $726000 | $1.2M | $1.2M | $2.0M | $1.7M | $1.6M | $1.4M | $1.2M | $116000 | $1.0M |
| Inventory | $323000 | $516000 | $530000 | $645000 | $665000 | $1.4M | $1.4M | 0 | 0 | 0 |
| Total Current Assets | $10.3M | $5.5M | $7.3M | $5.5M | $12.3M | $59.3M | $53.2M | $16.8M | $231.2M | $148.4M |
| Property, Plant & Equipment | $1.1M | $1.3M | $1.6M | $2.7M | $2.7M | $2.5M | $371000 | $6.3M | $59.5M | $78.1M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $24.1M | 0 | 0 |
| Intangible Assets | $230000 | $198000 | $162000 | $138000 | $130000 | $107000 | $25000 | $50.4M | $50.0M | $40.0M |
| Total Assets | $12.3M | $7.5M | $9.4M | $8.7M | $15.5M | $64.4M | $58.1M | $97.9M | $341.1M | $267.0M |
| Accounts Payable | $630000 | $1.4M | $683000 | $654000 | $494000 | $966000 | $1.5M | $6.9M | $10.3M | $20.5M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $49000 | $52000 | $56000 |
| Total Current Liabilities | $1.1M | $1.8M | $1.1M | $1.6M | $1.3M | $2.3M | $3.1M | $15.7M | $18.2M | $28.7M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.7M | $1.6M | $1.6M |
| Total Liabilities | $1.7M | $2.4M | $1.7M | $3.0M | $2.7M | $3.2M | $3.4M | $22.7M | $50.4M | $59.9M |
| Retained Earnings | -$72.6M | -$79.3M | -$84.5M | -$87.9M | -$89.5M | -$98.6M | -$105.9M | -$152.4M | -$231.7M | -$334.8M |
| Total Equity | $10.6M | $5.0M | $7.7M | $5.7M | $12.8M | $61.3M | $54.6M | $75.2M | $290.7M | $207.0M |
| Total Debt | 0 | 0 | 0 | $1.0M | $897000 | $524000 | $524000 | $2.6M | $4.1M | $3.3M |
| Net Debt | -$9.0M | -$3.4M | -$5.3M | -$1.4M | -$8.7M | -$55.4M | -$43.2M | -$6.7M | -$222.9M | -$141.5M |
| Working Capital | $9.2M | $3.6M | $6.2M | $3.9M | $11.0M | $57.1M | $50.1M | $1.2M | $212.9M | $119.7M |
Financial Health
| Debt / Equity | 0.01 |
| Current Ratio | 6.61 |
Profitability
| Return on Equity | -41.56% |
| Return on Invested Capital | -34.94% |
| Return on Assets | -29.70% |
| Gross Margin | -419.40% |
| Operating Margin | -34216.39% |
| Net Margin | -31812.57% |
Related companies: AVR · ELMD · HSDT · IVVD · MXCT · NNOX · NYXH
Explore sector: Healthcare · Medical - Devices
More sections of CATX: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks